Back
Engineering the Next Generation of Immunotherapies: Lessons from the First Approved T Cell Receptor-Based Therapy
Wednesday, January 27, 2027 at 3:30 PM to 4:00 PM · 30 min. (Europe/London)
Advanced Therapies Stage
Day 1 - Wednesday 27th January
Advanced Therapies
Information
Key points to be covered in the session:
Rationale for developing TCR based therapies
Overcoming key challenges to build the ImmTAX platform
Lead programme was approved in 2022, validating the approach in patients
Now executing a broad clinical pipeline across 3 different therapeutic areas and developing the next generation of ImmTAX molecules
Speakers
Annelise Vuidepot
SVP, Chief Science & Technology Officer and UK Site Head
Immunocore